Juan Carlos Rodríguez-Manzaneque

10PUBLICATIONS
53CO-AUTHORS
Haematological tumoursEnergy generation, conversion and storage (excl. chemical and electrical)Molecular targetsMedical molecular engineering of nucleic acids and proteinsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 25, 2026
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab.

|Feb 03, 2026
ADAMTS proteases in extracellular vesicles: emerging mediators of extracellular matrix dynamics and disease progression.

Carlos Peris-Torres, Juan Carlos Rodríguez-Manzaneque

|May 22, 2025
Loss of the extracellular protease ADAMTS1 reveals an antitumorigenic program involving the action of NIDOGEN-1 on macrophage polarization.

Rita Caracuel-Peramos, Francisco Javier Rodríguez-Baena, Silvia Redondo-García

|Aug 02, 2024
NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression.

Belén Lopez-Millan, Alba Rubio-Gayarre, Meritxell Vinyoles

|Jun 10, 2022
Gallic Acid: A Natural Phenolic Compound Exerting Antitumoral Activities in Colorectal Cancer via Interaction with G-Quadruplexes.

Victoria Sanchez-Martin, María Del Carmen Plaza-Calonge, Ana Soriano-Lerma

|Mar 25, 2022
The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia.

Belen Lopez-Millan, Paula Costales, Francisco Gutiérrez-Agüera

Pageof 2

Frequent Collaborators

3 joint publications

Heleia Roca-Ho

3 joint publications

Clara Bueno

2 joint publications

Narcís Fernandez-Fuentes

2 joint publications

Juan Ramón Tejedor